Back to Pressroom

Arlington, VA | Thursday, August 14, 2008

Champions Biotechnology, Inc. Retains The Investor Relations Group

Oct 25 2011 2:40 PM

Initiates Active Investor and Media Program

Champions Biotechnology, Inc. (OTCBB: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has retained the Investor Relations Group (IRG) to serve as its first investor relations and public relations firm in order to achieve greater recognition in the financial and media communities.

“Given the business progress we’ve made, it’s important for the Company to gain increased visibility,” said Douglas Burkett, PhD, President of Champions Biotechnology, Inc. “We look forward to embarking upon our relationship with IRG, one that will focus on building awareness and communicating our technology advantages and business objectives to the investment community and the media-at-large.”

“We believe that our Biomerk Tumorgrafts™ accurately predict the outcome of Phase II clinical trials,” said Dr. Manuel Hidalgo, Champions Biotechnology’s Chief Scientist. “The ability to test and predict which early stage drug candidates have the best chance to succeed in human clinical trials is of profound value and benefit to pharmaceutical and biotech companies, as well as to our own drug development program as we seek drug partnerships and acquisitions to expand our oncology drug pipeline. It is our goal to leverage the unique value of Biomerk Tumorgrafts to generate future revenues through royalty arrangements, partnerships, and acquisitions.”

IRG, a highly recognized, New York-based corporate communications firm, will strive to increase Champions Biotechnology’s public exposure, communicate the advantages of its technology, and explain its high potential growth objectives through a focused campaign. On the investor relations front, IRG will use its proprietary database of investors to introduce Champions Biotechnology to targeted members of the investment community through pre-qualified one-on-one introductions, e-mails to professionals that have opted-in to receive communication, interviews, and traditional outreach. In the public relations arena, IRG will strive to educate audiences of editors, writers, and segment producers of local and national trade and consumer print, radio, online, and broadcast media outlets about Champions Biotechnology’s technology and its role in the market.

About Champions Oncology, Inc.

Champions Oncology, Inc. (formerly Champions Biotechnology, Inc) is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions (“POS”) in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions (“TOS”) in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company’s Tumorgraft™ Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. The Company is building its Tumorgraft™ Technology Platform through the procurement, development and characterization of numerous Tumorgrafts™ within each of several cancer types. Tumorgrafts™ are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business. The Tumorgrafts™ are developed and tested through agreement with a United States-based preclinical facility.

The Company provides POS to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the Company offers Personalized Tumorgraft™ development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients’ tumorgrafts and understand the genetic make-up of their patient’s tumor enabling them to better select treatment regimens that may be efficacious to the patient

This press release may contain “forward-looking statements” (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as “believe,” “may,” “could,” “will,” “intend,” “expect,” “anticipate,” “plan,” and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company’s actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology’s Form 10-K for the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology’s future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology’s expectations, except as required by law.

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.